Datavault AI (NASDAQ: DVLT) has expanded its definitive licensing agreement with DataMeds AI Inc., extending its PharmacyChain blockchain-related technology beyond pharmaceutical distribution into commercial healthcare, healthspan and wellness applications. The expanded relationship is designed to support patient-controlled health data access, monetization and real-world asset tokenization across pharmacy, medical, laboratory and wearable device environments, leveraging a behavioral healthcare patent portfolio focused on medical logistics, IoT population health and AI-driven remote patient monitoring.
Under the amended agreement, Datavault AI will receive common shares representing approximately 19.9% of DataMEDS’ outstanding common stock upon closing of previously announced related transactions, replacing the preferred shares originally contemplated for tax optimization purposes. The companies said the agreement accelerates deployment of Datavault AI’s technology into the healthcare sector, targeting opportunities within the rapidly expanding global health and wellness market while enabling new patient-controlled data transaction models. For more details, see the full press release at https://ibn.fm/vBAxH.
This expansion underscores the growing importance of decentralized data control in healthcare, where patients are increasingly seeking ownership and monetization of their health data. By integrating Datavault AI’s Web 3.0 capabilities—including AI-driven data valuation and secure monetization—the partnership aims to create new revenue streams for patients and healthcare providers alike. The move also positions Datavault AI to tap into the global health and wellness market, which is expected to continue its rapid growth as digital health adoption accelerates.
Datavault AI's technology suite, which includes the Information Data Exchange for attaching physical objects to immutable metadata, is well-suited for healthcare applications such as digital twins of patient data and secure licensing of health information. The company’s platform serves multiple industries, including biotech and healthcare, and its Acoustic Sciences division features WiSA, ADIO and Sumerian technologies. The Data Science division leverages Web 3.0 and high-performance computing for data perception and monetization. More information is available at https://dvlt.ai.
The implications of this agreement are significant for the healthcare industry, as it moves toward patient-centric data models. By enabling patients to control and monetize their own health data, Datavault AI and DataMEDS are addressing key challenges in data privacy and interoperability. This could lead to more personalized healthcare and new business models in health insurance, research, and wellness. However, forward-looking statements in this announcement involve risks and uncertainties, as detailed in Datavault AI's SEC filings. The latest updates on DVLT are available at https://ibn.fm/DVLT.
